News

On a clear day in October, Shawn Hervey-Jumper, MD, rises before dawn at his home in the Oakland hills, a one-time horse ranch that he shares with his wife, two daughters, and a menagerie of animals, including a dog, three goats, and two kittens named Pepper and Cobbler, after his grandmother’s

The transition of a low-grade, slow growing brain tumor to a lethal one can be delayed if neurosurgeons remove as much as possible soon after diagnosis, according to the results of a study led by UC San Francisco. The findings run counter to other research indicating that extensive resection, or

Researchers at UC San Francisco (UCSF) have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells. Rejection mediated by antibodies—as opposed to the chemical assault initiated by immune cells

A fundamental challenge in drug development is the balance between optimizing a drug’s lock-and-key fit with its target and the drug’s ability to make its way across the cellular membrane and access that target. The search for cell-permeable drugs has conventionally focused on low-molecular weight

Glioblastomas (GBMs) are incurable brain tumors with a prognosis of about one-and-a half years on average. They are highly resistant to treatment and have defied all attempts at precision therapy. In their study published December 20 in Nature Cancer, first author Lin Wang, PhD and senior author

Scientists at UC San Francisco (UCSF) have engineered T-cells to produce a potent anti-cancer cytokine, but only when they encounter tumor cells. The immunotherapy eliminated melanoma and pancreatic cancer in mice without major side effects, and it offers a promising new strategy for fighting these